Molecular Tumour Board

The VCCC Molecular Tumour Board (MTB) is a multi-disciplinary style forum that provides opinion on the clinical implications of molecular pathology test results of tumours.

Each case is discussed on an individual, de-identified basis. Most MTB meetings also feature an educational presentation.

Discussion and assessment of molecular pathology results

The MTB is convened by Dr Stephen Luen with an expert group comprised of clinical and scientific staff from across the VCCC providing opinion on each case.  

The MTB educational and research presentations provide an excellent opportunity to learn more about personalised medicine. CPD points are available for meeting attendance. The MTB welcomes referrals from any clinician or multi-disciplinary team from VCCC members and collaborators.

Clinicians, scientists and students (from any organisation) are welcome to attend the meetings, which are held on Fridays.  

 

Meeting details

2:45 - 4pm 

If you would like to receive meeting agendas, be added to the mailing list or have other enquiries, please contact Louise Ludlow, VCCC Program Manager.

In accordance with our COVID-19 precautions the MTB will be run online until further notice.

Friday 19 June

Clinical presentation 1

Targeting the untargetable - example cases using AMG510 for tumours with KRAS G12C mutations

 Clinical presentation 2

Targeting oncogenic fusions - 2 example cases

  • Dr Huiling Xu (Molecular Pathology Diagnostic Development, Peter MacCallum Cancer Centre)
  • Dr Joep Vissers (Curation Scientist, Precision Oncology UMCCR and Department of Clinical Pathology, Peter MacCallum Cancer Centre)
  • Dr Owen Prall (Department of Pathology, Peter MacCallum Cancer Centre)
  • Dr Stephen Luen (Medical Oncology Consultant - Breast, Sarcoma, Early Drug Development and PhD student, Translational Breast Cancer Genomics and Therapeutics Lab - Loi Lab), Peter MacCallum Cancer Centre)

 

Friday 17 July

Education presentation 

Using RNA sequencing to find clinically relevant mutations

Clinical presentations (to be confirmed)

 

Friday 21 August 

Education presentation 

Circulating nucleic acids in advanced prostate cancer: prognosis, prediction and personalisation 

Clinical presentations (to be confirmed)

Future dates, speakers to be confirmed

Friday 18 September

Friday 16 October

Friday 20 November

Friday 18 December

Case submission

We welcome cases from clinicians whose patients have had molecular pathology testing performed as part of clinical care or research. Experts will provide advice and opinion regarding the clinical implications of the molecular pathology findings. Wherever possible, referring clinicians will also be advised on appropriate available clinical trials.

To submit a case to the MTB, please complete the MTB case form template and send via email to Louise Ludlow, VCCC Program Manager.